Skip to main content

Ponaxen 15 mg & 45 mg (Ponatinib)

This reference hub prioritizes regulatory and authoritative sources.

Regulatory sources

U.S. Food and Drug Administration

The FDA prescribing information provides current U.S. indications, dosage, warnings, adverse reactions, interactions and clinical pharmacology.

DailyMed

DailyMed provides the current U.S. ICLUSIG label record and identifies Takeda Pharmaceuticals America, Inc. as the packager for the listed product.

European Medicines Agency

The EMA EPAR provides European authorization information, indications, safety information and regulatory history for Iclusig.

Original development

FDA historical documents identify ARIAD Pharmaceuticals, Inc. as the applicant for the original Iclusig NDA.

Ponaxen-specific information

The manufacturer, authorization status and official regulatory documentation for Ponaxen are Everest Pharmaceuticals Ltd.

References for clinical evidence

The FDA clinical pharmacology review and EMA assessment documentation provide additional information about ponatinib’s development and clinical evidence.